{"id":2128,"date":"2006-12-01T12:00:00","date_gmt":"2006-12-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/wirksamkeit-und-sicherheit-von-thalidomid-in-der-primaeren-therapie-des-multiplen-myeloms"},"modified":"2006-12-01T12:00:00","modified_gmt":"2006-12-01T11:00:00","slug":"wirksamkeit-und-sicherheit-von-thalidomid-in-der-primaeren-therapie-des-multiplen-myeloms","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/wirksamkeit-und-sicherheit-von-thalidomid-in-der-primaeren-therapie-des-multiplen-myeloms","title":{"rendered":"Wirksamkeit und Sicherheit von Thalidomid in der prim\u00e4ren Therapie des multiplen Myeloms"},"content":{"rendered":"<p>Mit Thalidomid, Lenalidomid und Bortezomib (Velcade\u00ae) stehen inzwischen neue Wirkstoffe f\u00fcr die Behandlung des multiplen Myeloms (MM) zur Verf\u00fcgung. W\u00e4hrend der Proteasom-Inhibitor Bortezomib 2004 in Deutschland f\u00fcr die Behandlung des refrakt\u00e4ren oder rezidivierten MM zugelassen wurde, ist Thalidomid bisher nur in Neuseeland, Australien, der T\u00fcrkei und Israel f\u00fcr die Indikation refrakt\u00e4res oder rezidiviertes MM, nicht [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mit Thalidomid, Lenalidomid und Bortezomib (Velcade\u00ae) stehen inzwischen neue Wirkstoffe f\u00fcr die Behandlung des multiplen Myeloms (MM) zur Verf\u00fcgung. W\u00e4hrend der Proteasom-Inhibitor Bortezomib 2004 in Deutschland f\u00fcr die Behandlung des refrakt\u00e4ren oder rezidivierten MM zugelassen wurde, ist Thalidomid bisher nur in Neuseeland, Australien, der T\u00fcrkei und Israel f\u00fcr die Indikation refrakt\u00e4res oder rezidiviertes MM, nicht [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[501,4297,3209,286,1136,1137,974],"class_list":["post-2128","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-dexamethason","tag-ecog-studie","tag-gimema-studie","tag-melphalan","tag-multiples-myelom","tag-plasmozytom","tag-thalidomid"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2128"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2128\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}